|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||86.90 - 87.01|
|52 Week Range||19.62 - 87.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2018 - Mar 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||73.88|
Learn about Celgene Corporation and its key financial ratios, such as the debt-to-equity (D/E) ratio, operating margin and return on invested capital (ROIC).
Stock Monitor: Juno Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 23, 2018 / Active-Investors.com has just released a free research report on Celgene Corp. (NASDAQ: CELG ). If ...
Celgene Corporation today announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the previously announced tender offer by Celgene’s wholly owned subsidiary, Blue Magpie Corporation, for all issued and outstanding shares of common stock of Juno Therapeutics, Inc.
Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.
This year could be big for biotech mergers after Celgene and Sanofi, in a few days, spent $25 billion for three companies.
Moody's Investors Service ("Moody's") assigned a rating of Baa2 to the new senior unsecured note issuance of Celgene Corporation ("Celgene"). There are no changes to Celgene's existing ...
Vertex Pharmaceuticals, Amgen and Johnson and Johnson were among the big movers in the biotech and pharmaceutical sectors.
Celgene paid top dollar for Juno Therapeutics last month, but the biotech heavyweight may end up with buyer's remorse. Here's why.
NEW YORK, NY / ACCESSWIRE / February 2, 2018 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New ...
NEW YORK, Feb. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Guess? ...
PARIS/LONDON (Reuters) - French drugmaker Sanofi (SASY.PA) has agreed to buy Belgian biotech company Ablynx (ABLX.BR) for 3.9 billion euros (3.41 billion pounds), beating Novo Nordisk (NOVOb.CO) and marking its second big deal this month after buying Bioverativ (BIVV.O). The transaction is a further sign of accelerating merger and acquisition (M&A) activity in the global biotech sector and comes after Ablynx rejected a 2.6 billion euro offer from Denmark's Novo Nordisk. Sanofi said on Monday it would pay 45 euros per share in cash for Ablynx, a premium of 21 percent over its closing price on Friday, and more than double the price before Novo went public with its initial bid.